Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 4,556,267 shares, a growth of 47.4% from the October 15th total of 3,090,758 shares. Approximately 7.0% of the company’s stock are short sold. Based on an average daily trading volume, of 6,864,487 shares, the short-interest ratio is currently 0.7 days.
Acumen Pharmaceuticals Stock Performance
Shares of ABOS traded down $0.01 during midday trading on Tuesday, reaching $0.21. 1,024,850 shares of the stock were exchanged, compared to its average volume of 1,173,056. The company has a market cap of $15.19 million, a P/E ratio of -0.13 and a beta of 0.51. The stock’s 50 day simple moving average is $1.79 and its 200 day simple moving average is $2.39. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.17. Acumen Pharmaceuticals has a twelve month low of $0.19 and a twelve month high of $3.60.
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last announced its quarterly earnings results on Monday, October 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts expect that Acumen Pharmaceuticals will post -1.50 earnings per share for the current year.
Institutional Investors Weigh In On Acumen Pharmaceuticals
Analyst Upgrades and Downgrades
ABOS has been the subject of a number of research reports. Stifel Nicolaus downgraded shares of Acumen Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a report on Friday, October 30th. Weiss Ratings upgraded Acumen Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Lucid Cap Mkts cut Acumen Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Wall Street Zen downgraded shares of Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 17th. Finally, BTIG Research reduced their target price on shares of Acumen Pharmaceuticals to $1.00 and set a “buy” rating on the stock in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $1.00.
View Our Latest Research Report on ABOS
About Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease. Its research focuses on soluble amyloid beta oligomers, forms of the protein that the company believes contribute to the disease. The company’s lead investigational product, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target amyloid beta oligomers. Acumen has evaluated the treatment in clinical studies of people with early Alzheimer’s disease; it is investigational and has not been approved for commercial use.
See Also
- Five stocks we like better than Acumen Pharmaceuticals
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
